Table 2 Indication for liver biopsy and final diagnoses
Indication | N (%) |
|---|---|
Potentially malignant lesion | 1125 (50.5%) |
Hepatitis | 576 (25.8%) |
Transaminase elevation | 76 (3.4%) |
Abscess/cyst | 66 (3.0%) |
Hepatopathy, hepatomegaly | 161 (7.2) |
Lymphoma | 30 (1.4) |
Metabolic disorders (Wilsonâs disease, hemochromatosis, hemosiderosis) | 30 (1.4) |
Cirrhosis | 22 (1.0) |
Autoimmune disorder (autoimmune hepatitis, PBC, PSC) | 87 (3.9) |
Rejection reaction after liver transplantation | 4 (0.2) |
Jaundice of unclear origin | 1 (0.04) |
Thalassemia | 4 (0.2) |
Echinococcus infestation | 3 (0.1) |
NASH, ASH, steatosis | 13 (0.6) |
Cholestasis | 10 (0.5) |
Sarcoidosis | 11 (0.5) |
Bilioma | 2 (0.1) |
Hemangioma | 1 (0.04) |
Ascites | 3 (0.1) |
Stillâs disease | 1 (0.04) |
Alpha-1 antitrypsin deficiency | 2 (0.1) |
Vasculitis | 1 (0.04) |
Final diagnoses | N (%) |
Diffuse liver diseases | Â |
Viral hepatitis | 336 (15.1%) |
Autoimmune disorders | 43 (1.9%) |
Hepathopathy (NASH, ASH, steatosis, chronic hepatitis, drug-induced liver damage, nutritional-toxic damage, fibrosis, cirrhosis, liver necrosis, hepatosis, cholangitis, cholestasis, Budd-Chiari Syndrome) | 624 (28.0%) |
Metabolic disorders | 12 (0.5%) |
Rejection reaction following liver transplantation | 5 (0.2%) |
Sarcoidosis | 3 (0.1%) |
Carcinomas of hepatic origin (HCC, CCC) | 112 (5.0%) |
Benign liver tumors | Â |
Hemangioma | 14 (0.6%) |
Cysts | 13 (0.6%) |
Focal nodular hyperplasia | 13 (0.6%) |
Metastases | 590 (26.5%) |
Poorly differentiated carcinomas | 30 (1.4%) |
Echinococcosis | 4 (0.2%) |
Abscess | 42 (1.9%) |
Ascites | 1 (0.04%) |
Adenoma | 2 (0.1%) |
Bilioma | 2 (0.1%) |
Mucor mycosis | 1 (0.04%) |
Ethanol instillation (intervention) | 12 (0.5%) |
No pathological findings | 307 (7.3%) |
Non-diagnostic puncture | 63 (2.8%) |